Media Incorporated was launched in 2013 as a scientific research company. Biospherics is developing BSN272 as a treatment for high triglycerides, high cholesterol, and atherosclerosis, which can lead to heart attack and stroke.  The company also has BSN908 in testing as a drug treatment for abdominal aortic aneurysms (AAAs).  Biospherics recently completed a Phase 3 clinical trial investigating the use of BSN175 as a treatment for glycemic control in patients with Type 2 diabetes. is dedicated to keeping shareholders, the news media, and the public informed about business events, corporate capabilities, and other significant items affecting the Company, its markets, and its shareholders. Please check back often to access the latest news on

Media Inquiries should be addressed to:

Investor Relations
(301) 859-3230
info @